Welcome to Hmobio!Global leader in active molecules.
Find Your Distributors

Select Your Country or Region

 $ USD

For research purposes only. Not for human experiments
You are here:Home-Inhibitors & Agonists-Epigenetics-Bromodomain

Request The Product List ofBromodomain Bromodomain

Bromodomains are a family of evolutionarily conserved protein modules of approximately 110 amino acids that have been found in chromatin-associated proteins as well as nuclear histone acetyltransferases (HATs). Besides its role in chromatin remodeling, recent studies have identified that bromodomains, as acetyl-lysine binding domains, are able to recognize and bind ε–N-acetylated lysine residues in histone and non-histone proteins. The nuclear magnetic resonance (NMR) spectroscopic analysis reveals that the chemical structure of bromodomains, consisting of four left-handed α-helices (including αZ, αA, αB and αC) connected by two loops (ZA and BC loops), forms a deep hydrophobic cavity serving as the acetyl-lysine recognition site.

Cat. No. Product Name CAS No. Information
H9639

BRD8 inhibitor DN02

BRD8 inhibitor DN02 is a first-in-class selective and cellularly active probe for NuA4 factor BRD8 (BD1) with AlphaScreen IC50 of 48 nM, and Kd of 34 nM, displays IC50 of 0.64 uM in-cell engagement within BRET displacement assays, shows no affinity for BRD8 (BD2), CBP, and p300 (IC50>10 uM).
H9529

Amredobresib

 		1610044-98-8

Amredobresib is a potent inhibitor of BET,Amredobresib inhibits the binding of bromodomains to acetylated lysines on histone H3 and H4 and thus acts as important regulators of gene transcription; Amredobresib is useful for the research of acute myeloid leukemia (AML) and cancer
H9481

Inobrodib

 		2222941-37-7

Inobrodib(CCS-1477) is an orally, potent and selective p300/CBP bromodomain inhibitor, is targeted & differentiated from BET inhibitors in prostate cancer cell lines in vitro.
H9235

XS018661

 		878415-59-9

XS018661 is the first-in-class dual inhibitor of ENL with Kd of 754 ± 45 nM and its paralog AF9 with Kd of 523 ± 53 nM.
H9195

GSK778

 		2451862-42-1

GSK778 (iBET-BD1) is a potent and selective BD1 bromodomain inhibitor of the BET proteins, with IC50s of 75 nM (BRD2 BD1), 41 nM (BRD3 BD1), 41 nM (BRD4 BD1), and 143 nM (BRDT BD1), respectively; GSK778 phenocopies the effects of pan-BET inhibitors in cancer models.
H9191

NVS-CECR2-1

 		1992047-61-6

NVS-CECR2-1 is a non-BET family Bromodomain (BRD) inhibitor, is a potent and selective cat eye syndrome chromosome region, candidate 2 (CECR2) inhibitor. NVS-CECR2-1 binds CECR2 BRD with high affinity (IC50=47 nM; KD=80 nM); NVS-CECR2-1 exhibits cytotoxic activity and induces apoptosis against various cancer cells by targeting CECR2 as well as via CECR2-independent mechanism.
H9108

(+)-JQ-1-aldehyde

(+)-JQ-1-aldehyde is the aldehyde form of (+)-JQ1. (+)-JQ-1-aldehyde can be uesd as a precursor to synthesize PROTACs, which targets BET bromodomains.
H8855

Pelabresib

 		1380087-89-7

Pelabresib(CPI-0610)is a potent, selective, and cell-active BET inhibitor. CPI-0610 inhibits BRD4-BD1 with an IC50 of 39 nM, and with an EC50 value of 0.18 μM for MYC.
H8709

NHWD-870

 		2115742-03-3

NHWD-870 is a potent BRD4 inhibitor with IC50 of IC50 = 2 or 1.6 nM , and is about 50-fold more potent than JQ1.NHWD-870 is an oral bet inhibitor, which has good permeability in lung and SCLC tumors.
H8523

GSK046

 		2474876-09-8

GSK046 (iBET-BD2) is a potent, selective and orally active bromodomain inhibitor of BD2 of the BET proteins, with IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively.

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
© Copyright 2020 HmoBio. All Rights Reserved. Products are only for research use
沪ICP备2020027822号-1